Target cells for lithium in different forms within a heterogeneous hepatocarcinoma-29 population
- Authors: Gavrilova Y.S.1, Bgatova N.P.1, Solov’eva A.O.1, Trifonova K.E.1, Lykov A.P.1, Borodin Y.I.1, Konenkov V.I.1
-
Affiliations:
- Research Institute of Clinical and Experimental Lymphology
- Issue: Vol 10, No 4 (2016)
- Pages: 284-289
- Section: Article
- URL: https://journals.rcsi.science/1990-519X/article/view/212121
- DOI: https://doi.org/10.1134/S1990519X16040076
- ID: 212121
Cite item
Abstract
Liver cancer is an aggressive and heterogeneous human tumor. Lithium compounds block proliferation and induce apoptosis of hepatocarcinoma cells, but cannot cause the death of an entire population of tumor cells. The aim of this study was to reveal morphological types of target cells for different lithium preparations on the basis of their action on hepatocarcinoma-29 cells. The viability of hepatocarcinoma-29 cells was assessed by the MTT test. A dose-dependent decrease in viability was revealed upon addition of native and nanosized lithium carbonate and citrate. Target cells for lithium salts were revealed based on the morphological criteria for five differentiation stages of hepatocarcinoma-29 cells. It was shown that hepatocarcinoma- 29 proliferating cells of differentiation stages I and II are the target cells for native and nanosized lithium citrate, while differentiated cells of differentiation stages III and IV are the target cells for nanosized lithium carbonate. It was revealed that hepatocarcinoma-29 cells are more sensitive to nanosized lithium salts rather than to their native forms. This makes it possible to affect tumor growth more effectively.
About the authors
Yu. S. Gavrilova
Research Institute of Clinical and Experimental Lymphology
Author for correspondence.
Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060
N. P. Bgatova
Research Institute of Clinical and Experimental Lymphology
Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060
A. O. Solov’eva
Research Institute of Clinical and Experimental Lymphology
Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060
K. E. Trifonova
Research Institute of Clinical and Experimental Lymphology
Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060
A. P. Lykov
Research Institute of Clinical and Experimental Lymphology
Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060
Yu. I. Borodin
Research Institute of Clinical and Experimental Lymphology
Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060
V. I. Konenkov
Research Institute of Clinical and Experimental Lymphology
Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060
Supplementary files
